ArticlePathologie (Heidelberg, Germany)2026
POLQ and DNA-PK inhibition in muscle-invasive bladder cancer : Enhancing radiosensitivity with novel DNA damage response inhibitors to improve radiotherapy outcomes.
Article in Pathologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMuscle-invasive bladder cancer (MIBC) includes histological subtypes such as urothelial carcinoma (UC) and the rarer, prognostically unfavorable, squamous cell carcinoma (SCC). Standard treatment is radical cystectomy, while alternatives like chemotherapy or radiotherapy are particularly limited in SCC. Radiosensitizers, such as DNA-dependent protein kinase (DNA-PK) and DNA polymerase theta (POLQ) inhibitors, could selectively enhance radiotherapy effects in tumor cells and represent promising approaches for clinical translation.
objectiveThis study analyzed the radiosensitizing effects of DNA-PK and POLQ inhibition ex vivo in patient-derived MIBC cell lines of UC and SCC subtypes. MATERIALS AND
methodsThe DNA-PK inhibitor AZD7648 (DNA-PKi) and the POLQ inhibitor ART558 (POLQi) were tested ex vivo in patient-derived SCC (p-SCC; n = 3) and UC (p-UC; n = 3) cell cultures. Effects were assessed in combination with ionizing radiation (IR) using XTT cell viability assays (IC50), clonogenic survival assays, γH2AX immunofluorescence, and comet assays.
resultsDNA-PKi strongly radiosensitized MIBC cultures ex vivo, reducing IC50-XTT values by 74-99% and survival rates by 34-64%. Under POLQi +2 Gy, IC50 decreased by 7-13%, whereas under POLQi +8 Gy it increased by 11-24%, with only ~5% reduction in survival. DNA-PKi markedly delayed DNA repair (comet tail moments 38-40%, γH2AX foci increased 11.9-13.1-fold), while POLQi showed minimal effects (comet tail moments 22-33%, γH2AX foci increased 5.4-6.0-fold).
conclusionDNA-PKi radiosensitized MIBC cells more effectively than POLQi, particularly SCC. DNA damage response (DDR) inhibitors thus have therapeutic potential in MIBC, depending on the target protein and tumor subtype.
Indexed as
Identifiers
41295990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.